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Highlights ►  
► -HCB stimulates the angiogenic switch, increasing VEGF expression in a xenograft 
model. ► -HCB enhances VEGFR2 expression, and activates its downstream pathways in 
HMEC-1. ► -HCB induces COX-2 and VEGF expression protein levels in AhR-dependent 
manner in HMEC-1. ► -HCB increases HMEC-1 migration and neovasculogenesis 
involving AhR, COX-2 and VEGFR2. ►  
 
Abstract 
Exposure to environmental pollutants may alter proangiogenic ability and promotes tumor 
growth. Hexachlorobenzene (HCB) is an organochlorine pesticide found in maternal milk 
and in lipid foods, and a weak ligand of the aryl hydrocarbon receptor (AhR). HCB induces 
migration and invasion in human breast cancer cells, as well as tumor growth and 
metastasis in vivo. In this study, we examined HCB action on angiogenesis in mammary 
carcinogenesis. HCB stimulates angiogenesis and increases vascular endothelial growth 
factor (VEGF) expression in a xenograft model with the human breast cancer cell line 
MDA-MB-231. Human microvascular endothelial cells HMEC-1 exposed to HCB (0.005, 
0.05, 0.5 and 5 µM) showed an increase in cyclooxygenase-2 (COX-2) and VEGF protein 
expression involving AhR. In addition, we found that HCB enhances VEGF-Receptor 2 
(VEGFR2) expression, and activates its downstream pthways p38 and ERK1/2. HCB 
induces cell migration and neovasculogenesis in a dose- ependent manner. Cells 
pretreatment with AhR, COX-2 and VEGFR2 selective inhibitors, suppressed these effects. 
In conclusion, our results show that HCB promotes angiogenesis in vivo and in vitro. HCB-
induced cell migration and tubulogenesis are mediat by AhR, COX-2 and VEGFR2 in 
HMEC-1. These findings may help to understand the association among HCB exposure, 
angiogenesis and mammary carcinogenesis. 
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Epidemiological data show increases in incidence and prevalence of diseases associated 
with endocrine-disrupting chemicals, such as breast and prostate cancer, diabetes, obesity, 
and decreased fertility over the last 50 years (De Coster et al., 2012). Hexachlorobenzene 
(HCB) is an organochlorine pesticide well known as a widespread environmental pollutant. 
Despite a long-term ban on its use as a fungicide, HCB is a by-product in several processes, 
such as production of chlorinated solvents (Polder et al., 2009). Regional studies 
demonstrated the presence of this pollutant in human breast milk (Der Parsehian, 2008). 
Animal exposure to HCB elicits a number of effects such as thyroid disruption (Chiappini 
et al., 2009), immunological disorders (ATSDR, 2002) and co-carcinogenesis in rat 
mammary tumors (Peña et al., 2012). We have also rep rted that HCB induces cell 
migration and activates c-Src/HER1/STAT5b and HER1/E K1/2 signaling pathways in the 
human breast cancer cell line MDA-MB-231 (Pontillo et al., 2011). In addition, we have 
also observed that the pesticide increased MDA-MB-231 cell invasion and metastasis in 
different breast cancer experimental models in mice (Pontillo et al., 2013). 
 
HCB is a dioxin-like compound and a weak ligand of the aryl hydrocarbon receptor (AhR) 
(Hahn et al., 1989), which is a ligand-dependent transcription factor that modulates 
processes such as angiogenesis (Roman et al., 2009), proliferation and migration (Dietrich 
and Kaina, 2010). Upon dioxin binding, AhR can translocate to the nucleus where it 
regulates transcription of several genes including cyclooxygenase-2 (COX-2) (Degner et 
al., 2007). On the other hand, AhR-dioxin may release c-Src from its cytosolic complex, 
which can stimulate growth factor receptors, like th  vascular endothelial growth factor 
receptor 2 (VEGFR2) (García-Martín et al., 2013). 
 
Angiogenesis, the formation of new blood vessels from preexisting vasculatures, is 
necessary for many physiologic functions, while abnormal angiogenesis is usually 
considered as a sign of several diseases including ca cer. Healthy vessels are arranged in a 
hierarchical manner, whereas the tumor vasculature is disorganized and morphologically 
abnormal. Tumors vessels are leaky, in part due to the deficient perivascular support, but 
also due to abundant expression of the vascular endothelial growth factor A (VEGFA) 
(Fukumura and Jain, 2007). VEGFA acts on tumor endothelial cells to increase their 
proliferation, survival, migration and permeability, and by inhibiting vessel maturation 
(Greenberg et al., 2008). VEGF which is secreted by epithelial and endothelial cells, exerts 
its effects through binding to the receptor tyrosine kinases vascular endothelial growth 
factor –receptor 1 (VEGFR1) and VEGFR2, of which VEGFR2 is believed to be the main 
signal transducer in endothelial cells (Koch et al., 2011). VEGFR2 mediates the full range 
of VEGF responses in endothelial cells, like proliferation, migration and formation of the 
vascular tube. These physiological responses activate downstream mediators, including 
ERK1/2, c-Src, Akt, endothelial nitric oxide and p38 MAPK (Koch et al., 2011). Enhanced 
COX-2-induced synthesis of prostaglandin E2 (PGE2) stimulates cancer cell proliferation, 
promotes angiogenesis (Gately, 2000) and increases metastatic potential (Kakiuchi et al., 
2002). Increase in COX-2 mRNA and protein levels are known to be associated with 
esophageal, head and neck, breast, lung, prostate, and other cancers, indicating a close 
involvement of COX-2 in tumor progression and other pathological phenotypes in various 
malignant tumors (Tsuji et al., 2001). 
 
In previous studies, we found that HCB increases MDA-MB-231 cell invasion, and 
enhances mammary tumor growth and metastasis in different breast cancer models in mice 
(Pontillo et al., 2013). The aim of the present study was to investigate the effect of HCB on 
angiogenesis in mammary carcinogenesis. We sought to evaluate HCB capability to induce 
in vivo angiogenesis, using a xenograft model of breast cancer with MDA-MB-231 cell 
line. Furthermore, we examined the effect of HCB on cell proliferation, migration and 
neovasculogenesis in HMEC-1. We also investigated whether the AhR, COX-2 and 
VEGFR2 are involved in HCB-induced effects. 
2. Materials and Methods 
 
2.1.Chemicals 
HCB (>99% purity, commercial grade) was obtained from Aldrich-Chemie GmbH & Co. 
(Steinheim, Germany). Anti-COX-2, anti-AhR and anti-VEGF antibodies were purchased 
from Abcam Ltd. (Cambridge, UK). Anti-VEGFR2, anti-phospho-p38 and anti-phospho-
ERK1/2 antibodies were obtained from Cell Signaling Technology Inc., (Beverly, MA). 
Anti-ERK1/2 was purchased from Upstate (Lake Placid, NY), and anti-p38 was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-β-Actin, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and 4,7-
orthophenanthroline (PHE) were purchased from Sigma Chemical Co. (St Louis, MO). The 
specific inhibitors for COX-2, N-[2-(Cyclohexyloxy)-4-nitrophenyl] methanesulfonamide 
(NS-398) and for AhR, α-naphthoflavone (ANF), as well as antibiotic–antimycotic, 
trypsine and glutamine were obtained from Sigma Chemical Co. (St. Louis, MO). The 
inhibitor for VEGFR2, 4-Hydroxy-3-benzimidazol-2-ylhydroquinolin-2-one (ABYO) was 
purchased from Calbiochem (CAS 144335-37-5, Merck Millipore). The enhanced 
chemiluminescence kit (ECL) was from GE Healthcare Lif Sciences (Buckinghamshire, 
UK). DMEM high glucose culture medium was purchased from HyClone Laboratories, Inc. 
(Logan, UT). Matrigel was purchased from Becton Dickinson Biosciences (San José, CA). 
Fetal bovine serum was obtained from Invitrogen Life Technology (Carlsbad, CA). All 
other reagents used were of analytical grade.  
 
2.2. Mammary tumor- induced angiogenesis  
Six-week-old female nude Swiss mice (La Plata Labortory Animal Facility, Buenos Aires, 
Argentina) were maintained in a controlled environme t: 24 ± 2 °C, 50 ± 10% relative 
humidity, and a 12–12 hour light/dark cycle. Female nude mice were housed into germ free 
environmental conditions. Animals were given free access to a powdered certified rodent 
diet obtained from a commercial source (ACA- Nutrición Animal, 16-014007 Rata-Ratón) 
and given tap water ad libitum. Tumor cells induced angiogenesis was quantified using an 
in vivo bioassay previously described (Monte et al., 1997). HCB (0.3, 3 and 30 mg/kg body 
weight) was dissolved in corn oil and then administered to female mice by intraperitoneal 
injection (i.p.) (0.1 ml) three times a week during 4 weeks (n=5 mice per group). Then, 
MDA-MB-231 cells (5x104) in 0.1 ml DMEM were inoculated intradermically (i.d.) in both 
flanks of female nude mice. On day 5, animals were uthanized, the skin from the 
angiogenic site was carefully separated from the underlying tissues and the vascular 
response was observed in that place with a dissecting microscope (Konus USA 
Corporation, Miami, FL) at a 7.5 X magnification and photographed with an incorporated 
digital camera (Canon Power Shot A45, Canon USA, Inc. Lake Success, NY).  Photos were 
projected on a reticular screen to count the number of vessels per mm2 of skin. 
Angiogenesis was quantified as vessel density, calculated as the total number of vessels 
divided by the total number of squares. To detect VEGF protein levels in skin mice, skin 
from the angiogenic sites was dissected and homogenates were prepared. All the 
procedures were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals, National Research Council, USA. This research project was evaluated 
and accepted by the Institutional Animal Care and Use Committee (CICUAL) of School of 
Medicine, University of Buenos Aires, Argentina (Res.1146/2011). The HCB doses used in 
this model were the same we assayed previously in our laboratory. We have observed that 
these doses increased mammary tumor volume and weight, and significantly enhanced 
metastatic focus in mice lungs and liver (Pontillo et al., 2013). These concentrations are 
similar to those found in the environment. The HCB exposition to human populations 
varies among different countries. It has been detect d levels of HCB in serum of umbilical 
cord (1 mg/kg) and in maternal serum (0.6 mg/kg) in China (Guo et al., 2014). Other 
authors have analyzed HCB levels in human serum samples in France (0.02 mg/kg) (Saoudi 
et al., 2014), and in Italy (0.043 mg/kg) (Mrema et al., 2013). 
 
2.3. Cell culture and treatment 
HMEC-1 is an immortalized cell line of human microvascular endothelial cells. It retains 
the characteristic of normal human microvascular endothelial cells in morphology, 
phenotype and function. HMEC-1 cells (Centers for Disease Control, Atlanta, GA, USA) 
were cultured in high glucose DMEM supplemented with 10% fetal bovine serum (FBS), 
1% antibiotic-antimycotic mixture (10, 000 Units/ml penicillin, 10 mg/ml streptomycin 
sulphate, and 25 µg/ml amphotericin B). After 24 hours of starvation with DMEM 2% FBS, 
cells at 70–80% confluence were treated with HCB (0.005, 0.05, 0.5 and 5 µM) dissolved 
in absolute ethanol. Final ethanol concentration in each treatment was 0.5% and had no 
influence on the analyzed parameters as shown previously (Pontillo et al., 2011). In the 
present study, the highest HCB dose (5 µM) used is in the same range of order as that found 
in human serum from a highly contaminated population (To-Figueras et al., 1997). In 
addition, the HCB dose of 0.5 µM is similar that observed in human serum samples from 
general population in France (Saoudi et al., 2014). For inhibitors treatment, cells were 
pretreated for 3 hours with the specific inhibitors dissolved in dimethyl sulphoxide 
(DMSO), ABYO for VEGFR2, NS-398 for COX-2, and α-naphthoflavone (ANF) or 4,7-
orthophenanthroline (PHE) for AhR, in different cone trations according to the assay. 
Then, HCB or vehicle was added to the media in the presence or absence of inhibitors. 
 
2.4. Western blotting 
For VEGF immunodetection, skin from the angiogenic sites of mice was dissected and 
homogenates were prepared. Total cell protein lysates nd skin homogenates (30–100 µg)
were used by Western Blot analysis as described Pontillo et al., (2011). Polyclonal anti-
VEGF (1:500), anti-VEGFR2 (1:500), anti-COX-2 (1:500) or monoclonal AhR (1:500) 
antibodies were used. Polyclonal anti-phosho-ERK1/2 ( :500), anti-phospho-p38 (1:250), 
anti-p38 (1:500) and monoclonal anti- ERK1/2 (1:500) were used. After incubation, 
membranes were washed 5 times with TBS-T (TBS 0.1% Tween 20), and the suitable 
peroxidase-conjugated anti-species-specific antibodies (1:1000) were used for protein 
detection. The immune complexes were visualized by enzyme-linked enhanced 
chemiluminiscence kit (ECL, Amersham Biosciences Inc., UK) and quantified by scanning 
laser densitometry in a Fotodyne (Foto/Analyst), Gel-Pro Analyzer 3.1. Monoclonal Anti-β 
Actin (1:2000) antibody was used as control blottings. 
 
2.5. Proliferation assay 
The measurement of cell proliferation was evaluated by MTT [3-(4, 5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] colorimetric assay. This process requires active 
mitochondria, and even freshly dead cells do not cleave significant amounts of MTT. The 
cell viability and cell number are proportional to the value of absorbance measured by 
spectrophotometry at 570 nm. Briefly, 4x103 HMEC-1 cells were seeded in 96-well plates, 
and maintained in high glucose DMEM 10% FBS for 24 h. The next day, medium was 
removed and high glucose DMEM 2% FBS was added. After 24 hours of starvation, 
medium was removed and HCB (0.005, 0.05, 0.5 and 5 µM) or ETOH, in high glucose 
DMEM 3% FBS was added for 24 or 48 h. Finally, MTT (0.5 mg/ml) solution dissolved in 
high glucose DMEM was added to each well and incubated for 4 h at 37°C. Formazan 
crystals were dissolved in 100 µl DMSO, and the absorbance of the solution was measur d 
at 570 nm using the microplate reader Synergy HT (Biotek Instruments, Inc., USA). 
 
2.6. Migration assay 
The HMEC-1 capability to migrate was evaluated by scratch motility assay. 4 x106 HMEC-
1 cells were plated in a 6-well plate and grown overnight to confluency in DMEM, with 
10% FBS. Next, the cells were serum starved for 24 hours in DMEM 2% FBS. The 
monolayer was scratched with a pipette tip, washed with PBS to remove floating cells, and 
then were exposed to different concentrations of HCB (0.005, 0.05, 0.5 and 5 µM) in 3% 
FBS, or vehicle for 18 hours. Then, the scratched ar a was photographed at 0 and 18 hours, 
and the distance of wound healing in each well was evaluated (D t0= distance at 0 hours; D 
t18= distance at 18 hours). Then, the migration rate was calculated by D t0 –D t18 /(D t0 x 
100). For assays performed in the presence of specific VEGFR, COX-2 and AhR inhibitors, 
cells were pretreated for 3 hours with different inhibitors dissolved in DMSO: 0.1 or 1 µM 
ABYO for VEGFR2, or 10 µM NS-398 for COX-2, or 1 or 2 µM ANF for AhR. HCB 0.5 
µM or vehicle was added to the media during 18 hours in the presence or absence of 
inhibitors, and then were washed with PBS.  
 
2.7. Neovasculogenesis assay 
Matrigel (50 µl aliquots) was gelled at 37˚C for 1 h. After starving with high glucose 
DMEM 2% FBS, HMEC-1 (1x105 cells) were plated in 96 well in DMEM 3% FBS 
containing ETOH or HCB (0.005, 0.05, 0.5 and 5 µM), and the formation of capillary-like 
structures was photographed 24 hours later. Quantification of the total tube length and the 
number of branch points were performed using Image J program. For assays performed in 
the presence of specific VEGFR, COX-2 and AhR inhibitors, cells were pretreated for 3 
hours with 0.1 µM ABYO for VEGFR2, 1 µM NS-398 for COX-2, or 0.1 µM ANF for 
AhR. HCB 0.5 µM or vehicle was added to the media during 24 hours in the presence or 
absence of inhibitors, and then were washed with PBS.  
 
2.8. Statistical analysis 
For in vivo studies, we used n=5 mice per group. Data were evaluated by one-way 
ANOVA, followed by Tukey post-hoc test to identify significant differences between 
controls and treatments. Differences were considered significant when p-values were <0.05. 
Results represent the mean ± SD of at least three independent experiments. 
3. Results 
 
3.1. In vivo study of angiogenesis 
To evaluate the potential role of HCB to promote angiogenesis in vivo, MDA-MB-231 cells 
were injected into the mammary fat pad of female nude mice previously HCB (0.3, 3 and 
30 mg/kg b.w.)-treated three times a week during 4 weeks. After 5 days, the animals were 
euthanized and the inoculated sites were photographed and the number of vessels/mm2 was 
counted in the skin. Our results showed that HCB treatment (3 and 30 mg/kg b.w.) 
significantly enhanced (20 and 40%) the angiogenic switch, inducing the formation of 
blood vessels (Fig. 1A and B). To detect VEGF protein l vels, skin from the angiogenic 
sites was dissected, homogenates were prepared, and VEGF was evaluated by Western 
Blot. Our findings indicate that HCB (3 and 30 mg/kg b.w.) exposure increases VEGF 
protein expression (90 and 110%) in mice skin (Fig. 1C). 
 
 
Fig. 1. HCB promotes angiogenesis in a mouse MDA-MB-231 xenograft model. MDA-
MB-231 cells were injected into the mammary fat pad of female nude mice previously 
HCB (0.3, 3 and 30 mg/kg b.w.)-treated three times a week during 4 weeks. After 5 days, 
animals were euthanized and the inoculated sites were photographed and were projected 
onto a reticular screen to count the number of vessels/mm2 in skin. (A) Skin photographs of 
HCB or vehicle–treated mice. (B) Number of vessels/mm2 in HCB or vehicle-treated mice 
inoculated with MDA-MB-231 cells. (C) VEGF protein levels in mice skin evaluated by 
immunoblot.  Western Blot from one representative experiment is shown in the upper 
panel. Quantification by densitometry scanning of the immunoblots is shown in the lower 
panel. Data are expressed as means ± SD of three ind pe dent experiments with n=5 mice 
per group. Asterisks indicate significant differencs vs. vehicle (*p<0.05, **p<0.01, 
***p<0.001), ANOVA and Tukey post hoc test. 
 
3.2. HCB alters VEGF secretion and VEGFR2 protein levels in HMEC-1 
VEGF is secreted by epithelial and endothelial cells.  Therefore, we sought to evaluate if 
HCB has a direct action on endothelial cells, in vitro. For this purpose we explore whether 
HCB alters VEGF secretion in HMEC-1. Cells were trea ed with HCB (0.005, 0.05, 0.5 and 
5 µM) during 24 hours. The secretion of VEGF was evaluated in the conditioned medium 
of the cells, whereas the intracellular VEGF levels were analyzed in whole-cell lysates. As 
shown in Figure 2A, HCB had no effects on VEGF protein levels in cell lysates; in 
contrast, VEGF secretion was significantly enhanced by all assayed doses (76, 106, 91 and 
62%). We also evaluated VEGFR2 protein expression in this cell line. Our results show 
that HCB-treatment resulted in significantly increas d VEGFR2 protein levels, only at 0.5 
µM (39%) (Fig. 2B).  
Based on previous observations that AhR can regulate VEGF levels in HMEC-1 cell line 
(Roman et al., 2009), we evaluated if HCB-induced VEGF secretion is mediated through 
the bind of this pollutant to their receptor. The pr treatment with two structurally different 
AhR antagonists (0.1 µM ANF or 5 µM PHE), blocked HCB-induced VEGF secretion (Fig. 
2C). These results indicate clearly that HCB-enhanced VEGF secretion is mediated by AhR 
in HMEC-1 cells. 
 
Fig. 2. HCB alters VEGF secretion and VEGFR2 protein levels. HMEC-1 human 
microvascular endothelial cells were treated with HCB (0.005, 0.05, 0.5, and 5 µM) or 
vehicle (ETOH) during 24 hours. HMEC-1–conditioned medium was used to measure 
secreted VEGF protein levels and whole-cell lysates w re used to analyze intracellular 
VEGF (A) or VEGFR2 (B) protein levels by Western blot. (C) Role of AhR in HCB-
mediated VEGF secretion. Cells were pretreated for 3 hours with 0.1 µM ANF or 5 µM  
PHE and then exposed to HCB (0.5 µM) or vehicle during 24 hours, in the presence or 
absence of inhibitors. Values were normalized by immunoblotting using anti-β-Actin 
antibody. Western blots from one representative experiment are shown in the upper panels. 
Quantification by densitometry scanning of the immunoblots is shown in the lower panels. 
Data are expressed as means ± SD of three independent experiments. Asterisks indicate 
significant differences vs. vehicle (*p< 0.05, **p<0.01), ANOVA and Tukey post hoc test. 
Crosses indicate significant differences vs. HCB (0.5 µM), (+p< 0.05 and +++p<0.001), 
ANOVA and Tukey post hoc test. 
 
3.3. HCB action on AhR and COX-2 protein expression in HMEC-1 
We examined next the effect of HCB on AhR expression at 24 hours of treatment. Our 
results show that HCB (0.05, 0.5 and 5 µM) significantly increased AhR protein levels in a 
dose-dependent manner (100, 139 and 160% respectively) (Fig. 3A). 
The inhibition of COX-2 activity in animal models has been associated with a decrease of 
new blood vessel production in tumors, and an increase in tumor cell apoptosis (Kobayashi 
et al., 2004). Because VEGF up-regulates COX-2 mRNA, protein and e zymatic activity 
levels in HMEC-1 (Tamura et al., 2002), we next analyzed whether HCB could alter COX-
2 protein expression in this cell line. Cells were treated with different doses of HCB (0.005, 
0.05, 0.5 and 5 µM) during 24 hours, and cell lysate  were analyzed by Western Blot. Fig. 
3A shows that HCB significantly increased COX-2 levels at all assayed doses (50, 45, 48 
and 50% respectively).  
In order to evaluate if AhR could be mediating HCB-enhanced COX-2 levels, cells were 
pretreated for 3 hours with ANF (0.1 µM) or PHE (5 µM) and then exposed to HCB (0.5 
µM) or vehicle during 24 hours. Fig. 3B clearly demonstrated that HCB enhances COX-2 
protein levels through an AhR- dependent mechanism. 
 
Fig. 3. HCB increases AhR and COX-2 protein expression in HMEC-1. (A) Cells were 
treated with HCB (0.005, 0.05, 0.5, and 5 µM) or vehicle (ETOH) during 24 hours. Whole-
cell lysate was used to analyze AhR protein levels and COX-2 protein levels by Western 
Blotting. (B) Role of AhR in HCB-induced COX-2 protein levels. Cells were pretreated for 
3 hours with 0.1 µM ANF or 5 µM PHE and then exposed to HCB (0.5 µM) or vehicle 
during 24 hours, in the presence or absence of inhibitors. Whole-cell lysate was used to 
analyze COX-2 protein levels by Western Blotting. Data were normalized to β-Actin 
expression. Western blots from one representative experiment are shown in the upper 
panels. Quantification by densitometry scanning of the immunoblots is shown in the lower 
panels. Data are expressed as means ± SD of three ind pendent experiments. Asterisks 
indicate significant differences vs. vehicle (*p< 0.05, **p<0.01 and ***p<0.001), ANOVA 
and Tukey post hoc test. Crosses indicate significat differences vs. HCB (0.5 µM), ( 
+++p<0.001), ANOVA and Tukey post hoc test. 
 
3.4. HCB activates VEGFR2 in HMEC-1  
VEGFR2-specific ligands induce signaling pathways known to operate downstream of 
most tyrosine kinase receptors such as extracellular signal-regulated kinase 
(ERK)/mitogen-activated protein kinase (MAPK), and the stress kinase p38 MAPK (Koch 
et al, 2011). Because HCB increases VEGF protein levels, we examined whether the 
pesticide activates these pathways. HMEC-1 was treated with HCB (0.005, 0.05, 0.5 and 5 
µM) during 5 minutes, and then ERK1/2 and p38 phosprylation were evaluated by 
Western Blot. As shown in Figure 4A and B, the pesticide increased ERK1/2 
phosphorylation (150, 147 and 165%), as well as p38 phosphorylation (72, 50 and 64%) at 
HCB 0.05, 0.5 and 5 µM, respectively. 
Further, we examined the ability of VEGFR2 to mediate ERK1/2 and p38 activation when 
HMEC-1 cells were treated with HCB (0.5 µM). The pretreatment with VEGFR2 inhibitor 
(0.1 µM ABYO), blocked HCB-induced p38 and ERK1/2 phosphorylation (Fig. 4C). These 
results indicate that HCB-induced ERK1/2 and p38 phos orylation is mediated by 
VEGFR2 activation in HMEC-1 cells. Consistently, VEGF treatment resulted in the 
phosphorylation of ERK1/2 in a similar manner as that elicited by HCB (Supplementary 
Figure). To determine whether HCB-induced activation of VEGFR2 could involve COX-2 
and AhR, HMEC-1 cells were preincubated for 3 hours in the presence or absence of AhR 
inhibitor (0.1 µM ANF) or COX-2 inhibitor (1 µM NS-398), and then exposed to HCB (0.5 
µM) for 5 min. As shown in Fig. 4D, ANF and NS-398 completely blocked HCB-induced 
ERK1/2 and p38 phosphorylation. In this respect, we have also observed that 1 nM TCDD, 
a strong AhR agonist, induced ERK1/2 activation in a similar manner as that elicited by 0.5 
µM HCB. Further, when we incubated cells in the presence of 4,7-orthophenanthroline 
(PHE), a structurally ANF not related inhibitor of AhR, we found that ERK1/2 
phosphorylation was blocked by two inhibitors by a similar manner (Supplementary 




Fig. 4. HCB activates VEGFR2 in HMEC-1 (A) Phospho-ERK1/2 and total ERK1/2, (B) 
phospho-p38 and total p38. Cells were exposed to HCB (0.005, 0.05, 0.5 and 5 µM) or 
vehicle during 5 minutes. Whole-cell lysate was used to analyze phospho-ERK1/2 and 
phospho-p38 and total protein levels by Western Blot. (C) Role of VEGFR2, and (D) roles 
of AhR and COX-2 in HCB-mediated activation of ERK1/2 and p38. Cells were pretreated 
for 3 h with 0.1 µM ABYO (for VEGFR2) in (C), and pretreated for 3 hours with 0.1 µM 
ANF (for AhR) or 1 µM NS-398 (for COX-2) in (D) and then exposed to HCB (0.5 µM) or 
vehicle during 5 minutes, in the presence or absence of inhibitors. Whole-cell lysate was 
used to analyze phospho-ERK1/2 and phospho-p38 and total protein levels by Western 
Blot. A western blot from one representative experim nt is shown in the upper panels. 
Quantification by densitometry scanning of the immunoblots is shown in the lower panels. 
Data are expressed as means ± SD of three independent experiments. Asterisks indicate 
significant differences vs. vehicle (*p< 0.05, **p<0.01), ANOVA and Tukey post hoc test. 
Crosses indicate significant difference vs. HCB (0.5 µM), (+p< 0.05, ++p<0.01 and 
+++p<0.001), ANOVA and Tukey post hoc test. 
 
3.5. HCB effect on cell proliferation and migration  
VEGFA acts on endothelial cells to increase their proliferation, survival and migration 
(Greenberg et al., 2008). Because we have demonstrated that HCB increases VEGF 
secretion levels we next examined the ability of the pesticide to alter HMEC-1 cell 
proliferation. Cells were treated with different HCB doses (0.005, 0.05, 0.5 and 5 µM) 
during 24 and 48 hours and MTT assay was made. Our res lts show that HCB did not alter 
this parameter (data not shown).  
We next examined whether HCB exposure affects HMEC-1 cell migration. Then, wound 
healing assay was made at different HCB doses (0.005, .05, 0.5 and 5 µM), and the 
scratched area was photographed at 0 and 18 hours. Finally, the distance of wound width 
was measure on photographed area. We observed that the pesticide induces an 
enhancement on cell migration at all assayed doses (Fig. 5A). The activation of VEGFR2 
and COX-2 has been reported to mediate several aspects of tumor growth and progression, 
including migration, invasion and angiogenesis (Koch et al., 2011; Gately, 2000). It has 
also been shown that cell migration is regulated by AhR and its toxic ligands (Barouki et 
al., 2007). To determine whether VEGFR2, COX-2 and AhR are involved in HCB-induced 
cell migration, HMEC-1 cells were pretreated for 3 hours with the specific inhibitors, 0.1 
and 1 µM ABYO for VEGFR2, 10 µM NS-398 for COX-2 and 1 and 2 µM ANF for AhR. 
Next, wound healing assay was made at HCB 0.5 µM, in the presence or absence of 
inhibitors. Our results show that the specific inhibitors prevented HMEC-1 cells migration, 




Fig. 5. HCB-induces HMEC-1 cell migration. (A) Wound healing assay with HMEC-1 
cells exposed to HCB (0.005, 0.05, 0.5 and 5 µM) or vehicle for 18 hours. (B) Role of AhR, 
COX-2 and VEGFR2 in HCB- mediated cell migration. Cells were pretreated with specific 
inhibitors (1 and 2 µM ANF for AhR, 10 µM NS-398 for COX-2 and 0.1 and 1 µM ABYO 
for VEGFR2) and then were exposed to HCB 0.5 µM for 18 hours. The cell monolayer was 
scratched with a pipette tip, and then treated with HCB for 18 hours, or pretreated for 3 
hours with inhibitors and then exposed at HCB (0.5 µM), and relative wound closure was 
observed under microscope and photographed. Migration rate (%) was calculated on the 
photography of scratched area, measuring the distance of wound width at 0 and 18 h. 
Asterisks indicate significant differences vs. contr l (*p< 0.05, **p< 0.01), ANOVA and 
Tukey post hoc test. Crosses indicate significant difference vs. HCB (0.5 µM), 
(+++p<0.001), ANOVA and Tukey post hoc test. 
 
3.6. In Vitro neovasculogenesis assay 
Because HCB promotes angiogenesis in vivo, and increases VEGF secretion in HMEC-1, 
we next examined the pesticide effect on neovasculogenesis in vitro in this cell line. 
Briefly, the formation of HMEC-1 capillary-like structures in marigel was analyzed under 
treatment with different HCB doses (0.005, 0.05, 0.5 and 5 µM). Our data indicate that 
HCB significantly induced neovasculogenesis, enhancing total tube length (82, 77, 123 and 
127 %) as well as branching points (100, 97, 130 and 125 %) in a dose-dependent manner 
(Fig. 6A). To investigate, whether COX-2 and VEGFR2 were involved in HCB-induced 
neovasculogenesis, HMEC-1 cells were pretreated with specific inhibitors (1 µM NS-398 
for COX-2 and 0.1 µM ABYO for VEGFR2). As shown in the Figure 6B, NS-398 and 
ABYO abrogated HCB-induced tubulogenesis. It has also been shown that 
neovasculogenesis is regulated by AhR in HMEC-1 cells (Roman et al., 2009). Therefore 
we have also investigated whether AhR was involved in HCB-induced neovasculogenesis. 
Our results show that the specific AhR-inhibitor, 0.1 µM ANF, suppresses HCB-induced 
tubulogenesis (Fig. 6B). Altogether, these data indicate that COX-2, VEGFR2 and AhR are 
implicated in HCB-induced neovasculogenesis in this cell line. 
 
Fig. 6.Neovasculogenesis induced by HCB in HMEC-1 cells. (A) Photographs of 
capillary –like tube formation in Matrigel with cells exposed to HCB (0.005, 0.05, 0.5 and 
5 µM). (B) Role of AhR, COX-2 and VEGFR2 in HCB-mediated neovasculogenesis. Cells 
were pretreated with specific inhibitors (0.1 µM ANF for AhR, 1 µM NS-398 for COX-2 
and 0.1 µM ABYO for VEGFR2) for 3 hours, and then were exposed to HCB 0.5 µM for 
24 hours. The total tube length and branching points were calculated and represented as 
mean ± SD. Asterisks indicate significant differencs versus control (*p< 0.05, **p< 0.01), 
ANOVA and Tukey post hoc test. Crosses indicate significant difference vs. HCB (0.5 
µM), (+ p<0.05, ++p<0.01, +++p<0.001), ANOVA and Tukey post hoc test. 
 
4. Discussion 
Accumulating literature suggests that breast cancer may have an environmental origin and 
of particular concern are hormonally active environme tal agents such as organochlorine 
compounds that bio-accumulate within the food chain. However, there are few available 
data regarding organochlorine pesticides involvement in the modulation of angiogenesis, a 
critical step in tumor promotion. In this study, we observed that HCB-treatment induces 
neovascularization and VEGF expression, surrounding MDA-MB-231 inoculation site, thus 
stimulating the “angiogenic switch”. This is a prevascular phase during early tumor 
development where few or no tumor cells are angiogenic. As virtually all solid tumors are 
neovascularized by the time they are detected, is more interesting to evaluate the effect of 
the pesticide in this step. These data confirm our previous findings, demonstrating that 
HCB increased tumor growth in a xenograft model with MDA-MB-231 in nude mice 
(Pontillo et al., 2013). Other authors also found that prenatal exposure to bisphenol A 
increased the relative vascular area and VEGF expression in mammary glands in rats 
(Durando et al., 2011).  
  
VEGFR2 transduces VEGF responses in endothelial cells, via ERK1/2 and p38 pathways, 
regulating endothelial survival, proliferation, migration and formation of the vascular tube 
(Koch et al., 2011). Our data revealed that HCB activates VEGFR2 through an AhR and 
COX-2-dependent mechanism in HMEC-1. Besides, we observed that HCB increases 
VEGF secretion levels in this cell line. In this resp ct, other authors observed that the 
polychlorinated biphenyl PCB104, increases VEGF expr ssion in HMEC-1 cells (Eum et 
al., 2004). Furthermore, our results demonstrated that HCB increases COX-2 protein levels 
in HMEC-1. Similarly Anderson et al, (2011), demonstrated that the polychlorinated 
biphenyl PCB126, increased COX-2 mRNA expression in human umbilical vascular 
endothelial cells (HUVEC). Moreover, in this study we observed that HCB increases AhR 
protein levels in HMEC-1. We also demonstrated thatHCB-induced VEGF secreted levels 
and COX-2 protein levels are mediated by AhR. It is well known the role of AhR in 
angiogenesis. In this respect, Roman et al., (2009), reported that the lack of AhR expression 
in mice severely impairs their capacity to support the growth and angiogenesis of tumors, 
suggesting that an AhR-competent microenvironment is eeded for such an effect. On the 
other hand, we have shown that HCB enhances VEGFR2 protein levels, which has been 
correlated with breast cancer and poor survival (Ryden et al., 2010). Other authors found 
that VEGFR2 expression was up-regulated by VEGF in HMEC-1 cells (Hervé et al., 2006). 
Hence, our results suggest that increased VEGF secreted levels, might be associated with 
HCB-induced VEGFR2 protein levels.  
 
Angiogenesis is a complex process including endothelial cell proliferation, migration, 
basement membrane degeneration, and new tube formati n, involved in a variety of 
physiologic processes, as well as pathological mechanisms as cancer (Carmeliet and Jain, 
2000). Herein, we observed that HCB doesn't modify cell proliferation or viability in 
HMEC-1 cells. Recent studies found that organochlorine pesticides lindane and 
chlordecone increased endothelial cell proliferation (Clere et al., 2012). Conversely, other 
authors have demonstrated that 3-methylcholantrene is a potent anti-proliferative molecule 
in HUVEC, acting mainly through the AhR (Juan et al., 2006). In the present study, we 
show that HCB increases HMEC-1 cell migration and neovasculogenesis involving AhR, 
COX-2 and VEGFR2 proteins. 
In respect to the effective HCB doses in vitro, we observed that the pesticide enhances the 
AhR protein expression, as well as VEGFR2 activation levels at 0.05 to 5 µM. Similarly, 
we found that the pesticide increases cell migration and tubulogenesis at all doses, but has 
greater effect to the higher doses (0.5 and 5 µM). Therefore, we observed that there is a 
relationship between the pesticide effect on the activ tion of the important molecules for 
angiogenesis, and the biological actions such as migration and tubulogenesis. 
 
Our hypothesis is that HCB would be enhancing angiogenesis in breast cancer, in part, 
through the direct activation of the endothelial cel s. Particularly in HMEC-1, HCB might 
be binding to its receptor AhR and inducing VEGF expr ssion as reported previously by 
Roman et al., (2009), in this cell line. Other authors have found that AhR mediates TCDD 
induced VEGF expression and angiogenesis in mice (Takeuchi et al., 2009). Then, VEGF 
could be stimulating COX-2 levels. Similarly, Tamura et al., (2002), demonstrated that 
VEGF up-regulates COX-2 mRNA levels in HMEC-1. Furthermore, we thought that COX-
2 might be increasing VEGF expression in HCB treated HMEC-1. In this respect, it has 
been reported that VEGF expression is regulated by COX-2/ PGE2/ PGE2 receptor EP2-
EP4 pathway in gastric cancer cells (Liu et al., 2014). Then, HCB could be stimulating 
HMEC-1 migration and neovasculogenesis through an AhR, COX-2 and VEGFR2 
dependent mechanism (Fig.7). 
 
In conclusion, our results demonstrate for the first time, that HCB increases angiogenesis 
and VEGF expression i  vivo in a breast cancer model in mice. Furthermore, HCB-induced 
enhancement of HMEC-1 cell migration and neovasculogenesis are mediated by AhR, 
COX-2 and VEGFR2 proteins in this cell line. These findings may help understanding the 
association between HCB exposure, angiogenesis and m mmary carcinogenesis.  
 
Fig 7. HCB induces cell migration and tubulogenesis through an AhR, COX-2 and 
VEGFR2 dependent mechanism in HMEC-1. The overall scheme for HCB-induced 
effects on neovasculogenesis and cell migration in HMEC-1.  HCB might be binding to its 
receptor AhR and inducing VEGF expression. Then, VEGF could be stimulating COX-2 






New Figure: Effect of HCB on ERK1/2 phosphorylation in HMEC-1, and 
comparative effects of VEGF and TCDD. Phospho-ERK1/2 and total ERK1/2 protein. 
Cells were exposed to HCB (0.5 µM), VEGF (10 ng/ml), TCDD (1 nM) or vehicle during 5 
minutes. Cells were pretreated for 3 hours with 0.1 µM ANF or 5 µM PHE and then 
exposed to HCB (0.5 µM) or vehicle, in the presence or absence of inhibitors. Whole-cell 
lysate was used to analyze phospho-ERK1/2 and total protein levels by Western Blot. A 
western blot from one representative experiment is shown in the upper panel. 
Quantification by densitometry scanning of the immunoblots is shown in the lower panel. 
Data are expressed as means ± SD of three independent experiments. Asterisks indicate 
significant differences vs. vehicle (**p< 0.01, ***p<0.001), ANOVA and Tukey post hoc 
test. Crosses indicate significant difference vs. HCB (0.5 µM), (++p<0.01), ANOVA and 
Tukey post hoc test. 
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